Tetra Bio-Pharma

(TBP:TSXV)

Developer of Bio Pharmaceuticals and Natural Health Products

Tetra Bio-Pharma (TBP:TSXV) is a multi subsidiary publicly traded company. They are engaged in the development of Bio Pharmaceuticals and Natural Health Products containing Cannabis and other medicinal plant based elements.

Tetra Bio-Pharma is focused on combining the traditional methods of medicinal cannabis use with the supporting scientific validation and safety data required for for inclusion into the existing  bio-pharma industry by regulators, physicians, and insurance companies.

TBP takes the natural aspects of medical cannabis and applies the science of pharma to develop products that patients want, doctors want to prescribe and insurance companies will cover.

Tetra Bio-Pharma has 3 divisions:

Phyto Pain Pharma
A clinical stage research and development company focused on the development of Pharmaceutical products containing plant based Cannabinoids. Phyto Pain Pharma has a pipe line of products currently under development to treat a variety of ailments.

Agro Tek Health
A manufacturing and distribution company focused on acquiring, manufacturing, and distributing registered natural health products.

Grow Pros Cannabis
Focused on Identifying market opportunities in the legal cannabis industry for development of pharmaceutical and over the counter consumer products within the legal cannabis industry. Responsible for cultivation and sourcing of cannabis and industrial hemp on behalf of the TBP family of companies.

Developing
Bio Pharmaceuticals and Natural Health Products

Products:

  • Dried Cannabis Prescription Drug
  • Dronabinol XL – Sustained Release of THC
  • Dry Eye, Ocular Pain & Inflammation – Pure CBD
  • Topical Cream – Pure THC
  • Munchies B GONE gum
  • Topical product for pain management
  • Cardiovascular disease prevention, athletic performance, and well-being
  • Topical products for skin care
  • Topical for women – quality of life

Momentum Reports

MOMENTUM REPORTS — TETRA BIO PHARMA

Highlights:

  • Canadian-based pioneer, innovator and first to market in cannabis-based pharmaceuticals
  • Global medical marijuana market is estimated to reach US$55.8 billion by 2025
  • Tetra Bio-Pharma is the first and only bio-pharma company in North-America focused on cannabinoid (CBD) clinical stage pain relief products
  • Tetra is the only bio-pharma company currently running a double-blind Phase 1 study with organically-grown cannabis
  • Positive outcome from trials will result in for North-American Drug Identification Numbers (DIN), thus qualifying prescriptions for insurance coverage.
  • Strategic partnership with Aphria Inc. announced in November 2016 and solidified in April 2017

Recent News

OFFICIAL STOCK INFO

Schedule a time with Momentum to discuss further

TOP
Message Us
Loading...